A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics
Emily is an IPC Executive within the Faculty of Medicine team focussed on intellectual property management, supporting Imperial academics with commercial engagement, fostering collaborative research and negotiating out-licenses. Emily manages an IP portfolio which...
Imperial.Tech.Pitch: Affordable technologies for an ageing society centred on the premise that within 20 years, there will be 25% fewer taxpayers to pensioners in the UK than in 2020.
MyoLoop is a device that can simulate pathological conditions (e.g. hypertension), to study their progression, and the effects of therapeutic interventions on them.
A new 3D-culture methodology using stirred-tank bioreactors as a scalable platform for the production of hPSC-derived endothelial cells
A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.